ObjectiveTo systematically review the intervention of Baduanjin (eight-section brocade) in patients with diabetes. MethodsLiterature search was conducted in such databases as PubMed, EMbase, The Cochrane Library (Issue 8, 2013), CNKI, VIP and WanFang Data from the dates of establishment to August 2013. Randomized controlled trials (RCTs) on Baduanjin for patients with diabetes were included. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data and assessed the quality of included studies. Then, meta-analysis was performed using RevMan 5.1 software. ResultsA total of 10 studies involving 825 patients were included. The results of meta-analysis showed that, the Baduanjin group was superior to the control group in lowering fasting plasma glucose, 2-hour postprandial plasma glucose, glycosylated hemoglobin, and reducing the levels of total cholesterol and triglycerides, increasing the level of high-density lipoprotein, with statistically significant differences. However, There was no statistically difference in low-density lipoprotein between the two groups. ConclusionBaduanjin could lower the level of blood glucose, and it is also beneficial in blood lipids improvement for diabetes patients. Baduanjin is better than both conventional exercise and no exercise for diabetes patients. However, due to the limitation of quantity and quality of the included studies, this aforementioned conclusion should be further confirmed by conducting more large-scale highquality RCTs.
ObjectiveTo systematically evaluate the efficacy and safety of 125I seed interstitial implantation for lung cancer. MethodsWe searched PubMed, The Wiley Online Library, Elsevier, CNKI, VIP and WanFang Data from inception to February 2014 to collect randomized controlled trials (RCTs) of 125I seed interstitial implantation in the treatment of lung cancer. Two reviewers independently screened literature, extracted data and assessed the risk bias of included studies, and then meta-analysis was performed by using RevMan 5.1 software. ResultsA total of 23 RCTs involving 1 492 patients were included. The results of meta-analysis showed that:the effective rate (OR=3.43,95%CI 2.71,4.33,P<0.000 01), 1 year survival rate (OR=2.83, 95%CI 2.03 to 3.95, P<0.000 01) and 2 year survival rate (OR=2.49, 95%CI 1.60 to 3.88, P<0.000 01) in the 125I seed interstitial implantation group were higher than those in the control group, but the rate of postoperative complications was higher than that of control group (OR=19.72, 95%CI 11.63 to 33.45, P<0.000 01). In addition, there were no significant differences between both groups in the 3 year survival rate (OR=2.45, 95%CI 0.21 to 28.89, P=0.48) and the adverse reaction rate (OR=0.74, 95%CI 0.52 to 1.05, P=0.09). Conclusion125I seed interstitial implantation is effective in the treatment of lung cancer. It can improve treatment efficiency and short-time survival rate, but may increase the rate of complications such as pneumothorax, seed malposition, bleeding and so on. Due to the limited quality and quantity of included studies, more high quality and larger sample studies are needed to verify the above conclusion.
ObjectiveTo systematically evaluate the efficacy and safety of budesonide/formoterol combined with tiotropium versus budesonide/formoterol alone for Chinese patients with COPD. MethodsWe electronically searched databases including PubMed, EMbase, The Cochrane Library (Issue 3, 2015), CNKI, VIP and WanFang Data to collect randomized controlled trials (RCTs) about budesonide/formoterol combined with tiotropium vs. budesonide/formoterol alone for Chinese COPD patients from inception to March 2015. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was conducted by RevMan 5.3 software. ResultsA total of 15 studies involving 1123 Chinese patients were included. The results of meta-analysis showed that, compared with the budesonide/formoterol alone group, the budesonide/formoterol plus tiotropium group could significantly improve the levels of FEV1 (MD=0.19, 95%CI 0.12 to 0.25, P<0.00001), FVC (MD=0.35, 95%CI 0.14 to 0.57, P=0.001), FEV1% (MD=5.96, 95%CI 4.48 to 7.43, P<0.00001), FEV1% pred (MD=6.82, 95%CI 2.21 to 11.43, P=0.004), FEV1/FVC (MD=7.72, 95%CI 5.69 to 9.75, P<0.00001), mMRC (MD=-0.43, 95%CI -0.52 to -0.33, P<0.00001), CAT (MD=-1.45, 95%CI -2.26 to -0.64, P=0.0005), SGRQ (MD=-7.05, 95%CI -9.16 to -4.94, P<0.00001) and 6MWT (MD=32.52, 95%CI 16.68 to 48.37, P<0.00001). While there was no significant difference in adverse reaction rates between the two groups (OR=1.77, 95%CI 0.79 to 3.98, P=0.16). ConclusionCurrent evidence shows that budesonide/formoterol plus tiotropium can improve lung function and clinical symptom in Chinese patients with COPD. Due to the limited quality and quantity of included studies, more high quality studies are needed to verify the above conclusion.